1. Home
  2. KO vs AMGN Comparison

KO vs AMGN Comparison

Compare KO & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coca-Cola Company (The)

KO

Coca-Cola Company (The)

N/A

Current Price

$97.54

Market Cap

404.0B

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$468.02

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KO
AMGN
Founded
1886
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
404.0B
251.6B
IPO Year
2004
2002

Fundamental Metrics

Financial Performance
Metric
KO
AMGN
Price
$97.54
$468.02
Analyst Decision
Buy
Hold
Analyst Count
24
34
Target Price
$98.43
★ $431.81
AVG Volume (30 Days)
★ 15.5M
2.5M
Earning Date
10-27-2026
11-03-2026
Dividend Yield
★ 2.17%
2.15%
EPS Growth
23.58
★ 88.23
EPS
2.86
★ 14.79
Revenue
★ $47,941,000,000.00
$25,424,000,000.00
Revenue This Year
$5.23
$7.41
Revenue Next Year
N/A
$4.59
P/E Ratio
$34.15
★ $31.64
Revenue Growth
1.87
★ 8.83
52 Week Low
$67.27
$312.39
52 Week High
$97.73
$483.99

Technical Indicators

Market Signals
Indicator
KO
AMGN
Relative Strength Index (RSI) 69.05 64.01
Support Level $85.32 $326.58
Resistance Level N/A $483.99
Average True Range (ATR) 1.67 11.96
MACD 0.22 -0.26
Stochastic Oscillator 91.73 64.68

Price Performance

Historical Comparison
KO
AMGN

About KO Coca-Cola Company (The)

Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around 60% of its total revenue overseas, with sizable contributions from emerging economies in Latin America and Asia-Pacific.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: